Quotient Therapeutics Appoints Susan Keefe as CFO

Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, has appointed Susan Keefe as Chief Financial Officer (CFO).

Keefe has a 30-year tenure in finance, accounting and operations in the life sciences, most recently serving as the company’s acting CFO through her role at the company’s founder, Flagship Pioneering.

“Susan brings a powerful combination of strategic insight, operational rigor and experience building and scaling public and private life science organizations,” said Rahul Kakkar, MD, President and CEO of Quotient. “We are thrilled to have her join Quotient as we continue to leverage somatic genomics to build our internal and partnered portfolio.”

Experience

Prior to Flagship, Keefe served as the Interim CFO of Benson Hill. Previously, she was CFO of GreenLight Biosciences, where she steered financial strategies for a pioneering company developing RNA-based solutions with applications in both agriculture and human health. Before that, she held leadership roles in finance and administration at Danforth Advisors and Aushon Biosystems, and earlier in her career, she developed core financial acumen through roles at SeraCare Life Sciences, Procter & Gamble, and PwC.

Keefe holds an MBA in strategic management, finance, marketing, and entrepreneurship from the University of Chicago Booth School of Business, and a BBA in accounting from the University of Iowa.

“Somatic genomics has the potential to uncover novel biological insights that inform breakthrough therapies across a broad range of diseases,” Keefe said. “I look forward to joining the Quotient team and building a solid financial and operational foundation to support the Company’s long-term growth and value creation strategy.”